Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Neoplasm
Open-data reference.
11 US clinical trials · 7 currently recruiting
Active & Recent Trials
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Dana-Farber Cancer Institute
NCT06122896
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
NCT06400472
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06051695
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
SWOG Cancer Research Network
NCT06807437
Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study
Ohio State University Comprehensive Cancer Center
NCT05961982
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
Masonic Cancer Center, University of Minnesota
NCT06411795
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT05687123
Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
Eli Lilly and Company
NCT00267020
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
Takeda
NCT00034281
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Barbara Ann Karmanos Cancer Institute
NCT01420874
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
Mayo Clinic
NCT03033225
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 6 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Pancreatic Neoplasm Trial Landscape
ClinicalTrials.gov lists 11 US studies indexed under Pancreatic Neoplasm, and 7 of those are currently open to recruitment — roughly 64% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Pancreatic Neoplasm shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 9 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Pancreatic Neoplasm is led by Eli Lilly and Company with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 11 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Pancreatic Neoplasm?
PlainTrial tracks 11 US clinical trials for Pancreatic Neoplasm, of which 7 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Pancreatic Neoplasm?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.